Oxford Nanopore Technologies (ONT) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
22 Jan, 2026Executive summary
H1 2024 revenues reached £84.1m, up 12.4% year-over-year on a constant currency basis, with 74% from consumables.
Gross margin improved to 58.8%, up 120bps year-over-year, driven by product mix and operational improvements.
Adjusted EBITDA loss increased to £61.6m, reflecting higher operational expenses and investment, but loss reduced 6% sequentially from H2 2023.
Strong cash position of £397.1m at period end, further enhanced by a post-period equity raise of £78.2m.
Full-year guidance reaffirmed: 20%-30% underlying revenue growth at constant currency and ~57% gross margin.
Financial highlights
Revenue of £84.1m in H1 2024, with underlying growth at 12.4% at constant currency; reported revenue down 2.2% year-over-year.
Gross margin at 58.8%, with underlying improvements offsetting FX and mix headwinds.
Adjusted EBITDA loss increased 56% year-over-year to £61.6m, but improved sequentially from H2 2023.
Cash and liquid investments stood at £397.1m at 30 June 2024, down from £472.1m at FY23.
Working capital inflow of £6m (excluding assets placed with customers).
Outlook and guidance
FY24 guidance confirmed: 20%-30% underlying revenue growth at constant currency, gross margin ~57%.
H2 expected to see a step-up in revenue, especially in the Americas, driven by improved sales force efficiency and new product launches.
Medium-term targets: >30% CAGR revenue growth FY24–FY27, gross margin >62% by FY27, breakeven adjusted EBITDA in FY27, and positive cashflow in FY28.
Revenue expected to be second-half weighted (approx. 45:55 split).
COVID and EGP headwinds to be smaller in 2024, with FX headwinds moderating.
Latest events from Oxford Nanopore Technologies
- Clinical and applied markets drive growth as technology and partnerships expand adoption.ONT
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - FY25 revenue up 24.2% to £223.9m, with margin gains and EBITDA breakeven targeted for 2027.ONT
H2 20252 Mar 2026 - Long-read sequencing and multi-omics drive growth, with strong H1 results and expanding market reach.ONT
21st Annual Goldman Sachs European Medtech and Healthcare Conference22 Jan 2026 - Robust growth, margin gains, and new product traction position the business for sustained expansion.ONT
Bank of America Global Healthcare Conference 202420 Jan 2026 - Nanopore sequencing enables rapid, affordable genomics with strong growth and global health impact.ONT
Bernstein Annual Pan-European Strategic Decisions Conference20 Jan 2026 - Strong FY25 growth, innovation, and leadership transition drive global expansion.ONT
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - Surpassed growth targets, improved margins, and set a strong outlook with new innovations and partnerships.ONT
Fireside Chat15 Jan 2026 - FY25 revenue up 22% to £223–£224M, surpassing guidance with broad-based growth.ONT
H2 2025 TU12 Jan 2026 - High-accuracy, scalable sequencing drives clinical and population genomics growth worldwide.ONT
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026